hPSCreg®
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our Privacy Policy for details. This website uses cookies, learn more


GEMi022-A-3

Registration Summary:

GN-JY02-01-012(APP c.2149G>A)

The cell line is not validated yet.
GEMi022-A-3

General

Cell Line
hPSCreg name GEMi022-A-3
Cite as:
GEMi022-A-3
Alternative name(s)
GN-JY02-01-012(APP c.2149G>A)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 19th December 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider
Generator Shanghai Gemple Biotech Co.,Ltd (GEM)
Owner Shanghai Gemple Biotech Co.,Ltd (GEM)

External Databases
BioSamples SAMEA117481767

General Information
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information
Sex male
Ethnicity Chinese Han

Phenotype and Disease related information (Donor)
Diseases No disease was diagnosed.
Family history Not available
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)
BioSamples SAMEA115963429

Ethics

Also have a look at the ethics information for the parental line GEMi022-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General
The source cell information can be found in the parental cell line GEMi022-A.
Passage number reprogrammed P17

Reprogramming method
Vector type None

Vector free reprogramming
Type of used vector free reprogramming factor(s)
Protein
Protein

Other
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
–
SSEA-4
Yes
–
TRA 1-60
Yes
–
Morphology pictures

Microbiology / Virus Screening
HIV 1 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46,XY
APP_C_2149.jpg
Passage number: P24
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Alzheimer disease type 1
Synonyms
  • early-onset familial form of Alzheimer disease
  • Alzheimer disease 1, familial
  • AD
  • AD1
  • Alzheimer disease
  • Alzheimer disease 1
  • Alzheimer disease, early-onset, with cerebral amyloid angiopathy
  • Alzheimer disease, familial, 1
  • Alzheimer disease, late-onset, susceptibility to
  • Alzheimer disease, protection against
  • Alzheimer disease, susceptibility to
  • presenile and senile dementia
show more synonyms
Genetic modifications
APP (target)
Gene knock-in
cytoband location: 21p21
APP
cytoband location: 21p21
APP c.2149G>A is a known pathogenic APP mutation，that can cause Alzheimer disease type 1 (AD1).APP c.2149G>A is a missense change in the substitution of valine with isoleucine inAPP protein 717(p.Val717lle), it has been collected in ClinVar (lD: 18088) and is Heterozygous pathogenicity.
CRISPR-associated (CRISPR/Cas) System